Navigation Links
Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study

Basis Established for DNA-Guided Decision Support in Diabetes Drug Therapy

HARTFORD, Conn., Jan. 21 /PRNewswire/ -- Research by Genomas has shown statistically significant associations of certain genes in vascular and energy pathways to body mass index (BMI) and edema (fluid retention) in patients taking the thiazolidinedione (TZD) drugs pioglitazone and rosiglitazone. The study, co-authored with investigators from Joslin Diabetes Center Affiliate at The Hospital of Central Connecticut, Hartford Hospital and Yale, appears in the February 2009 issue of the leading laboratory medicine journal Clinica Chimica Acta. The findings are being used to develop a DNA-guided decision support system for diabetic pharmacotherapy.

TZDs are powerful diabetes drugs currently utilized in patients failing first-line therapy with metformin and sulfonylureas. Patients given TZDs typically are at greater risk of diabetic complications and represent an advanced stage of the disease. However, TZDs have been observed to have side effects of weight gain and abdominal obesity, which exacerbate the diabetic condition itself, and to cause edema and exacerbate congestive heart failure in certain patients. Individuals vary in their risk and there is no known method for predicting such side effects. FDA-mandated "black box" warnings on the drug labels underscore the urgent need to better understand the mechanisms underlying these potentially serious side effects. Uncertainties surrounding the use of these drugs may place patients at risk, reduce patient compliance, burden medical management and increase healthcare costs.

The study involved an analysis of patients taking either pioglitazone or rosiglitazone. A total of 222 cardiometabolic and neuroendocrine genes were selected and a physiogenomic analysis was performed. For BMI, the strongest associations were found among genes involved in energy homeostasis, adiposity, glucose metabolism, and lipid metabolism. For edema, associations were found among the genes involved in vascular inflammation or regulation, lipid metabolism and glucose metabolism.

"For the first time in diabetic care, we can assess that genes in interlocking cardiometabolic and neuroendocrine pathways can be integrated into a PhyzioType System, a multi-gene array and clinical model predictive of drug side effects," said Gualberto Ruano, M.D., Ph.D., President and CEO of Genomas. "Our existing PhyzioType Systems for statin neuro-myopathy and antipsychotic-related diabetes are now being complemented by a third one for TZD-induced cardiovascular side effects for comprehensive DNA-guided medicine in modern healthcare."


Genomas(R) Inc. is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs used to treat diabetes, and cardiovascular and psychiatric illnesses. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. Please visit for more information.

SOURCE Genomas Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
2. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
3. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
4. Amarin Announces Initiation of Cardiovascular Development Strategy
5. VIA Pharmaceuticals Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Informations Therapeutic Area Partnerships Conference
6. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
7. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
8. HealthAware Introduces Its VascularAware Cardiovascular Disease Module
9. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
11. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
Post Your Comments:
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of ... their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been ... Target to its list of well-respected retailers. This list includes such fine stores ...
Breaking Biology Technology:
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
Breaking Biology News(10 mins):